Orthofix Medical Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. Although the request identifies 2022 Q4, this filing reports annual results; the supplied text does not provide a clear standalone fourth-quarter income statement or quarterly revenue figure. Unless noted otherwise, 2022 results are Orthofix standalone and exclude SeaSpine.
Business context
Orthofix develops and sells spine, biologics, bone-growth therapy, and orthopedic products in approximately 68 countries. In 2022, Global Spine generated 76.7% of net sales and Global Orthopedics 23.3%. Orthofix completed its merger with SeaSpine on January 5, 2023; SeaSpine’s 2022 results are not included in this filing’s annual financial results. The company planned to reassess its reporting segments after the merger.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Net sales | $460.7 million | $464.5 million |
| Gross profit / gross margin | $337.2 million / 73.2% | $349.6 million / 75.3% |
| Operating loss | $13.3 million | $8.3 million |
| Net loss | $19.7 million; $0.98 per diluted share | $38.4 million; $1.95 per diluted share |
| EBITDA, company-defined non-GAAP | $12.6 million | $29.7 million |
| Cash from operating activities | $(11.5) million | $18.5 million |
| Capital expenditures | $23.2 million | $19.6 million |
| Free cash flow, company-defined non-GAAP | $(34.7) million | $(1.1) million |
| Cash and cash equivalents at year-end | $50.7 million | $87.8 million |
Cost of sales rose 7.5% while sales declined 0.8%, compressing gross margin by 2.1 percentage points. Sales and marketing expense was $228.8 million (49.7% of sales), general and administrative expense was $80.0 million (17.4%), and research and development expense was $49.1 million (10.6%). The company reported a $2.0 million income tax expense despite a pretax loss; valuation allowances were a significant factor in the tax provision.
Liquidity and debt: Current assets were $256.0 million and current liabilities $83.6 million at year-end. No borrowings were outstanding under Orthofix’s $300 million secured revolving facility at December 31, 2022. Orthofix subsequently borrowed $30 million on January 3, 2023 and another $15 million on March 3, 2023, including for working capital and merger-related costs. The facility matures October 2024 and is secured by substantially all of the borrowers’ personal property. Year-end finance lease liabilities were $19.9 million; operating lease liabilities were $7.0 million.
Changes versus 2021
- Net sales declined 0.8% reported; management described the constant-currency decrease as 1.5%. The filing’s sales table appears to show a conflicting positive constant-currency figure, so the direction should be verified against the filed financial tables.
- Global Spine sales declined 1.6% to $353.2 million. Spinal Implants fell 4.8% to $109.5 million; Bone Growth Therapies and Biologics were essentially flat.
- Global Orthopedics sales increased 1.9% reported to $107.5 million, or 11.0% on a constant-currency basis. Foreign exchange reduced sales by approximately $9.6 million in this segment.
- Gross margin fell from 75.3% to 73.2%, which management attributed to sales mix, inventory reserves, shipping and manufacturing costs, and foreign exchange.
- Operating cash flow shifted from positive $18.5 million to negative $11.5 million; year-end cash declined by $37.1 million. Inventory increased to $100.2 million from $83.0 million, and inventory turns fell to 1.2 from 1.4.
- Net loss narrowed, principally in comparison with 2021’s $11.8 million Global Orthopedics goodwill impairment and larger tax expense. In 2022, a $17.2 million reduction in the estimated Spinal Kinetics contingent consideration liability contributed a favorable operating item.
Outlook, risks, contingencies, and unusual items
- The merger creates a larger combined spine and orthopedics business, but entails integration costs, operational complexity, possible employee or customer disruption, and uncertainty about achieving anticipated synergies. Management said future results will include SeaSpine beginning in 2023; the filing provides no quantified revenue or earnings guidance.
- Management highlighted new-product development and commercial investment. 2022 milestones included FDA PMA approval for AccelStim, a bone-growth stimulator for certain fresh fractures, and a CGBio agreement to commercialize Novosis rhBMP-2 in the U.S. and Canada. SeaSpine’s FLASH navigation platform and further modules were planned for development or launch in 2023.
- Key business risks include reimbursement and healthcare cost pressures, intense competition, regulatory approval and compliance requirements (including the EU Medical Device Regulation), possible FDA reclassification of bone-growth stimulators, dependence on distributors and tissue suppliers, supply-chain disruption, foreign exchange, cyber risk, and the effects of elective-procedure volumes.
- Orthofix accrued $5.9 million for the Italian Medical Device Payback, disputed the measure’s legality, and cautioned the ultimate amount could differ. The remaining $30 million Spinal Kinetics revenue milestone was valued at zero at year-end because management did not expect it to be achieved by its deadline.
- Four merger-related stockholder lawsuits were voluntarily dismissed; additional demand letters and potential litigation were disclosed. The filing does not provide a clear estimate of potential loss for these matters.
- Management and the auditor concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2022. The independent auditor gave an unqualified opinion on the financial statements and internal controls.
Important facts for investors to verify
- Reconcile the filing’s conflicting constant-currency sales description and reported figure, and review the actual fourth-quarter results separately if quarterly performance is material to the analysis.
- Track post-merger revenue, margins, cash generation, integration costs, realized synergies, and the combined company’s revised segment reporting.
- Monitor liquidity after the subsequent $45 million facility draws, covenant compliance, debt repayment capacity, and merger-related cash uses.
- Assess inventory growth, reserve assumptions, sell-through, and cash conversion; inventory valuation was identified as a critical audit matter.
- Follow the Italian payback proceedings, merger-related claims, and any changes in regulatory, reimbursement, supplier, or product-liability exposure.